At a glance
ClinicalIndex Comparison RecordPhase 2Not Yet Recruiting· 74 target
Drug / intervention
Liposomal irinotecan +1 moredrug
Likely dose
Liposomal irinotecan 70mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer:a Multicenter, Phase I/II Trial.
In Brief
A Phase 2 clinical trial evaluating Liposomal irinotecan and Bevacizumab for Colorectal Cancer. Not yet recruiting, targeting 74 participants across 1 site.
Detailed Summary
To evaluate the efficacy and safety of liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Not Yet RecruitingOverdue
20252026
First PostedMay 2024
Enrollment StartJun 2024
Primary CompletionJun 2025
Study CompletionJul 2026
TodayJul 2026
First PostedMay 30, 2024
Enrollment StartJun 5, 2024
Primary CompletionJun 5, 2025
Study CompletionJul 1, 2026
TodayJul 1, 2026
Enrollment to primary: 1 yearPosted 2.1 years ago
Interventions
Liposomal irinotecandrug
Liposomal irinotecan will be given biweekly at a dose from 70mg/m2 to 90mg/m2.
Bevacizumabdrug
bevacizumab will be given biweekly at a dose of 5mg/m2